Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, including those with PD-L1-low tumors, compared with chemotherapy alone, according to results from the phase III COMPASSION-15 trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.

Login Or Register To Read Full Story